Business / Finance RSS Feed - Business / Finance

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer. [More]

UPMC WorkPartners receives A-rating from A.M. Best

UPMC WorkPartners has retained its financial strength rating of A- (Excellent) from A.M. Best, the world's oldest and most authoritative insurance rating and information source. [More]

DST Systems completes acquisition of Wealth Management Systems

DST Systems, Inc., a global provider of strategically unified data management, business processing, and customer communication solutions, today announced it has completed the previously announced acquisition of retirement plan rollover specialist Wealth Management Systems Inc. [More]
Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus Biotherapeutics today announced that they have entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are an important class of proteins that play a key role in the innate immune system. [More]
PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand. [More]
DelMar closes on $2.6 million registered direct placement

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering. [More]
STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand. [More]
Cyberonics, Sorin provide update on pending business combination

Cyberonics, Sorin provide update on pending business combination

Cyberonics, Inc. and Sorin S.p.A. today announced an update on various matters relating to their pending business combination (the "Transaction"). [More]
Cyberonics reports record worldwide net sales of $81.0 million for first fiscal quarter 2016

Cyberonics reports record worldwide net sales of $81.0 million for first fiscal quarter 2016

Cyberonics, Inc. today announced results for the quarter ended July 24, 2015. [More]
Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones. [More]

Equashield reports record revenue growth, expands production facilities for future growth

Equashield, a leading provider of Closed System Transfer Devices (CSTDs) for safe and simple handling of hazardous drugs, today announced a more than doubling of year-over-year revenue. [More]
Telesta closes US$28.6 million in private placement financing

Telesta closes US$28.6 million in private placement financing

Telesta Therapeutics Inc. announced today that it has closed a private placement financing of US$28.6 million. This transaction was led by several prominent U.S. healthcare investors, including Consonance Capital Investors, Boxer Capital of Tavistock Life Sciences and Omega Funds. In addition, certain members of the senior management team and board of directors of Telesta participated in the transaction. [More]
Kindara completes $5.3M in Seed funding

Kindara completes $5.3M in Seed funding

Kindara, a transformative women's health company that produces apps and devices that help women understand and achieve better results with their reproductive health, today announced the close of $5.3M in Seed funding, including the conversion of $1.9M in convertible notes. [More]

Bionik Laboratories begins share trading on OTCQX under existing ticker symbol BNKL

Bionik Laboratories Corp., a pioneering medical device and robotics company with a focus in developing transformational technologies and solutions for individuals with neurological disorders, announced that shares of the Company's common stock will begin trading today on the OTCQX® Best Market under its existing ticker symbol "BNKL." [More]
Applying a top restaurant model to healthcare communications: an interview with Brandi Robinson, Sanofi

Applying a top restaurant model to healthcare communications: an interview with Brandi Robinson, Sanofi

Communications professionals often are expected to be experts in all facets of the vast spectrum of communications, from brand, corporate, crisis and digital communications to corporate reputation and channel strategy and everything in between. [More]
Pittcon will be exhibiting at Recent Advances in Microbiology Research:  A BioConference Live 2015 Virtual Event

Pittcon will be exhibiting at Recent Advances in Microbiology Research: A BioConference Live 2015 Virtual Event

The field of microbiology, the study of minute organisms such as bacteria, viruses, archaea, and eukaryotes, is yielding startling new findings about their effects on people and the environment. Keeping current with these advances while keeping up with a demanding workflow can be challenging. [More]

Quest Diagnostics announces quarterly cash dividend of $0.38 per share

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on October 21, 2015 to shareholders of record of Quest Diagnostics common stock on October 6, 2015. [More]
Benitec prices initial public offering of 1,500,000 American Depositary Shares

Benitec prices initial public offering of 1,500,000 American Depositary Shares

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the pricing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec and warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares, at a price of US$9.21 per ADS and US$0.01 per warrant. [More]
BioElectronics reports Q2 financial results, publishes market surveys of ActiPatch Therapy

BioElectronics reports Q2 financial results, publishes market surveys of ActiPatch Therapy

BioElectronics Corporation, the maker of advanced drug-free consumer medical devices, today published on its second quarter financial results along with a market analysis of its long term follow up surveys of customers who are managing pain with ActiPatch Therapy. [More]
Hi-Tech acquires LG Sciences brand of Sports Nutrition and Bodybuilding products

Hi-Tech acquires LG Sciences brand of Sports Nutrition and Bodybuilding products

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and LG Sciences, one of the premier Sports Nutrition and Bodybuilding brands in the United States, today announced that Hi-Tech has acquired LG Sciences brand of Sports Nutrition products and Bodybuilding products. [More]
Advertisement
Advertisement